European Union Approves Darunavir for Treatment-Experienced Patients
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




European Union Approves Darunavir for Treatment-Experienced Patients

NEW YORK -- December 3, 2008 -- The European Commission has broadened the indication for darunavir (Prezista) in combination with ritonavir and other antiretroviral drugs for the treatment of HIV-1 infection in all treatment-experienced adult patients.

The extended indication was based on the 48-week analysis of the phase 3 TMC4/R in Treatment-Experienced Patients Naive to Lopinavir (TITAN) trial.

Results showed that 77% of patients in the darunavir/r arm (n=298) versus 67% of patients in the lopinavir/r arm (n=297) reached less than 400 copies/mL (P<.0001).

Darunavir was generally well tolerated. The majority of the adverse reactions reported in patients who initiated therapy with darunavir 600 mg co-administered with 100 mg ritonavir twice daily were mild to moderate in severity.

SOURCE: Johnson&Johnson

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities